Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LVE
|
|||
| Former ID |
DIB011863
|
|||
| Drug Name |
CPI-0610
|
|||
| Indication | Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 3 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [2] | ||
| Myelodysplastic neoplasm [ICD-11: 2A60] | Phase 1/2 | [2] | ||
| Myeloproliferative neoplasm [ICD-11: 2A20; ICD-10: D47.7] | Phase 1/2 | [2] | ||
| Company |
Constellation pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H16ClN3O2
|
|||
| Canonical SMILES |
CC1=NOC2=C1C3=CC=CC=C3C(=NC2CC(=O)N)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
|
|||
| InChIKey |
GCWIQUVXWZWCLE-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 1380087-89-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain and extraterminal domain protein (BET) | Target Info | Inhibitor | [2] |
| Bromodomain-containing protein 4 (BRD4) | Target Info | Modulator | [3], [4], [5], [6] | |
| KEGG Pathway | SNARE interactions in vesicular transport | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| WikiPathways | Chemical Compounds to monitor Proteins | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04603495) Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. | |||
| REF 4 | BET inhibitor resistance emerges from leukaemia stem cells.Nature.2015 Sep 24;525(7570):538-42. | |||
| REF 5 | Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. | |||
| REF 6 | Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.